Poster published at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting shows the final 5 year safety data from the Phase IIb breast cancer clinical trial. Final safety conclusions ...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent ...
Identifying GP2 specific T cell immune response at baseline prior to treatment with GP2 has potential to predict breast cancer recurrence risk and timing of recurrence A positive baseline immune ...
‒ Poster for GP2 Phase IIb clinical trial final efficacy analysis was presented during the 2020 San Antonio Breast Cancer Symposium (SABCS) today ‒ Phase IIb clinical trial was a prospective, ...
The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly migraine days versus ...
Most people find data privacy compliance to be complicated enough. So, when they encounter the concept of data mapping—something that isn’t an explicit requirement in any data privacy law—many find ...
You can’t have a successful data migration if you don’t map it out from the start. Learn what data mapping is and why it’s an important early step in data migration and transformation projects. Data ...
Final results of a phase I trial of PR104, a pre-prodrug of the bioreductive prodrug PR104A, given weekly to solid tumor patients. Background: Safety data are not yet available for the potential ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results